Mounjaro vs Zepbound: Same Drug, Different Brand Names — Complete Side-by-Side Comparison (2026)

Mounjaro and Zepbound contain the same active ingredient (tirzepatide), at the same weekly doses (2.5 → 15 mg), made by the same manufacturer (Eli Lilly). They are sold under different brand names because the FDA approves drugs by indication, not by molecule. Mounjaro is the type 2 diabetes brand. Zepbound is the chronic weight management + obstructive sleep apnea brand. The dominant practical difference is insurance: plans cover each only for its FDA-approved indication. This is the full side-by-side.

The short answer

• Same molecule: tirzepatide — a dual GIP / GLP-1 receptor agonist
• Same manufacturer: Eli Lilly and Company
• Same weekly doses: 2.5, 5, 7.5, 10, 12.5, and 15 mg subcutaneous, once weekly
• Same titration schedule: start at 2.5 mg for 4 weeks, increase by 2.5 mg every 4 weeks as tolerated
• Same boxed warning: thyroid C-cell tumors (rodent data; human relevance debated)
• Same contraindications: personal/family history of medullary thyroid carcinoma; multiple endocrine neoplasia syndrome type 2
• Different FDA-approved indications:
  • Mounjaro — type 2 diabetes mellitus (FDA-approved May 2022)
  • Zepbound — chronic weight management (FDA-approved November 2023) + obstructive sleep apnea in adults with obesity (added December 2024)
• Different self-pay pricing paths. Lilly publishes the LillyDirect Self Pay Journey Program for Zepbound vials ($299–$449/mo by strength) and KwikPen ($299–$699/mo). Mounjaro has no comparable DTC self-pay program — only the Mounjaro Savings Card for commercially insured patients.
• Different insurance coverage paths. Insurance plans cover each brand only for its FDA-approved indication. Documented in our verbatim payer policy articles for Cigna and Aetna.

Side-by-side comparison

Which one will your prescriber ask about?

The prescription depends on your FDA-approved indication, not your preference:

• If you have type 2 diabetes — your prescriber will write Mounjaro. Aetna's bulletin 5468-C and Cigna's CNF 360 both gate Mounjaro behind a metformin-first step (eGFR <30 or established CVD as bypass routes). See our Aetna PA guide for the verbatim metformin step language.
• If you have obesity (BMI ≥ 30) or overweight (BMI ≥ 27 with comorbidity) — your prescriber will write Zepbound. Aetna's 6947-C and Cigna's IP0206 both require a 6-month / 3-month documented behavioral and dietary modification trial respectively, plus the 11-condition comorbidity list for the BMI 27–29.9 pathway (Cigna).
• If you have moderate-to-severe obstructive sleep apnea (AHI ≥ 15) plus obesity — your prescriber will write Zepbound under the OSA pathway (added to the label in December 2024 per the SURMOUNT-OSA trial). This is the only Zepbound pathway that may unlock Aetna and Cigna Medicare Part D coverage, because the indication is non-weight-loss.
• If you have BOTH type 2 diabetes AND obesity — your prescriber will likely choose based on which indication is your insurance coverage path. Some patients have one indication covered (e.g., diabetes via Mounjaro) and the other denied (e.g., weight management via Zepbound). Off-label prescribing of Mounjaro for weight loss is legal but typically not insurance-covered.

Cost comparison: Mounjaro vs Zepbound in 2026

The pricing landscape diverged sharply in late 2025. Lilly launched the LillyDirect Self Pay Journey Program for Zepbound vials in December 2025 and aggressively expanded retail-channel pricing for the KwikPen. Mounjaro received no comparable DTC discount, only the Mounjaro Savings Card for commercially insured patients.

For the live channel-by-channel pricing across every brand plus compounded options, see our GLP-1 pricing index. Brand and compounded GLP-1s are generally HSA/FSA-eligible with a prescription per IRS Publication 502.

The off-label question

Patients with obesity but without type 2 diabetes sometimes ask whether they can fill Mounjaro instead of Zepbound to get a better price or to satisfy an insurance plan that has Mounjaro on a preferred tier. The answer is nuanced:

• Off-label Mounjaro for weight loss is legal — prescribers may legally write any FDA-approved drug for off-label use at their clinical discretion.
• Insurance plans typically deny it. Cigna CNF 360 and Aetna 5468-C both gate Mounjaro behind a type 2 diabetes diagnosis. Without that diagnosis, the PA system rejects.
• Cash-pay Mounjaro has no DTC discount (unlike Zepbound's LillyDirect $299–$449 vials), so there is no economic reason to prefer Mounjaro over Zepbound for cash-pay weight-loss use.
• The medication is identical. If you can access either brand, your clinical experience will be the same — the molecule, dose, and titration are identical.

Verification log

Every clinical claim above was verified against the verbatim Mounjaro and Zepbound DailyMed FDA labels (NIH-hosted) on 2026-05-09. Pricing data was verified live from manufacturer self-pay portals (LillyDirect), retailer programs (Costco CMPP via Sesame, Sam's Club, Amazon Pharmacy), and GoodRx the same day. PMID citations (SURMOUNT-1 35658024, SURPASS-2 34170647, SURMOUNT-OSA 38912654) were confirmed by direct PubMed fetch.